J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...

Johnson & Johnson ( JNJ 0.01%) has been a leading healthcare company in the world for decades, and it's one of the most ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson kicked off Q2 2025 pharma earnings season with a bang Wednesday, adding $2 billion to the midpoint of its ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Johnson & Johnson on Wednesday reported second quarter results that topped estimates and the company lifted its full-year outlook.

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

The S&P 500 ticked 0.3% higher on Wednesday, July 16, 2025, as President Trump sought to ease concerns that a dismissal of ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...